China Pharma (CPHI) 10-K 30 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 19, 2015	Jun. 30, 2014
Document and Entity Information
Entity Registrant Name	CHINA PHARMA HOLDINGS, INC.
Entity Trading Symbol	CHPI
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Entity Central Index Key	1106644
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		43,579,557
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Public Float			$9,443,423

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets:
Cash and cash equivalents	$5,295,790	$5,993,139
Banker's acceptances	458,233	336,003
Trade accounts receivable, less allowance for doubtful accounts of $33,350,109 and $13,301,622, respectively	24,851,086	45,147,602
Other receivables, less allowance for doubtful accounts of $60,325 and $43,064, respectively	272,199	175,739
Advances to suppliers	7,889,009	7,626,716
Inventory, less allowance for obsolescence of $6,934,044 and $8,027,126, respectively	15,321,856	24,677,120
Prepaid expenses	404,370	0
Total Current Assets	54,492,543	83,956,319
Advances for purchases of intangible assets	42,390,186	41,701,505
Property and equipment, net of accumulated depreciation of $6,640,718 and $5,264,350, respectively	33,881,878	30,241,337
Intangible assets, net of accumulated amortization of $4,186,273 and $3,812,992, respectively	1,317,221	1,711,793
TOTAL ASSETS	132,081,828	157,610,954
Current Liabilities:
Trade accounts payable	2,550,816	1,877,437
Accrued expenses	269,870	323,651
Other payables	1,401,470	1,312,361
Advances from customers	2,078,866	2,228,238
Other payables - related parties	1,354,567	1,354,567
Current portion of construction loan facility	1,629,062	0
Short-term notes payable	4,887,187	4,909,662
Total Current Liabilities	14,171,838	12,005,916
Non-current Liabilities:
Construction loan facility	11,403,438	12,484,183
Long-term deferred tax liability	252,707	176,414
Total Liabilities	25,827,983	24,666,513
Stockholders' Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.001 par value; 95,000,000 shares authorized; 43,579,557 shares and 43,579,557 shares outstanding, respectively	43,580	43,580
Additional paid-in capital	23,590,204	23,590,204
Retained earnings	62,848,901	88,896,276
Accumulated other comprehensive income	19,771,160	20,414,381
Total Stockholders' Equity	106,253,845	132,944,441
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$132,081,828	$157,610,954

CONSOLIDATED_BALANCE_SHEETS_PA

CONSOLIDATED BALANCE SHEETS PARENTHETICALS (USD $)	Dec. 31, 2014	Dec. 31, 2013
Stockholders equity number of shares par value and other disclosures
Allowance for doubtful accounts on trade accounts receivables	$33,350,109	$13,301,622
Allowance for doubtful accounts on other receivables	60,325	43,064
Allowance for obsolescence of inventory	6,934,044	8,027,126
Accumulated depreciation on property and equipment	6,640,718	5,264,350
Accumulated amortization on intangible assets	$4,186,273	$3,812,992
Preferred Stock, par or stated value	$0.00	$0.00
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par or stated value	$0.00	$0.00
Common Stock, shares authorized	95,000,000	95,000,000
Common Stock, shares issued	43,579,557	43,579,557
Common Stock, shares outstanding	43,579,557	43,579,557

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
REVENUES
Revenue	$24,927,707	$32,806,678
Cost of revenue	17,215,576	23,405,886
Inventory obsolescence	2,250,130	9,881,711
Gross profit (loss)	5,462,001	-480,919
Operating expenses:
Selling expenses	3,346,511	3,284,905
General and administrative expenses	1,716,760	2,404,338
Research and development expenses	2,798,557	1,683,244
Bad debt expense	20,643,035	10,752,991
Losses from natural disaster	2,276,519	0
Total operating expenses	30,781,382	18,125,478
Subsidy income	65,113	0
Loss from operations	-25,254,268	-18,606,397
Other income (expense):
Interest income	69,739	8,457
Interest expense	-785,804	-348,696
Net other expense	-716,065	-340,239
Loss before income taxes	-25,970,333	-18,946,636
Income tax expense	-77,042	-1,061,413
Net loss	-26,047,375	-20,008,049
Other comprehensive income (loss) - foreign currency translation adjustment	-643,221	4,435,923
Comprehensive loss	($26,690,596)	($15,572,126)
Loss per share:
Basic	($0.60)	($0.46)
Diluted	($0.60)	($0.46)

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Common Stock Shares	Common Stock Amount	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income	Total Stockholders' Equity
				USD ($)	USD ($)	USD ($)
Balance, at Dec. 31, 2012	43,579,557	43,580	23,590,204	108,904,325	15,978,458	148,516,567
Net loss for the year				($20,008,049)		($20,008,049)
Foreign currency translation adjustment					4,435,923	4,435,923
Balance, at Dec. 31, 2013	43,579,557	43,580	23,590,204	88,896,276	20,414,381	132,944,441
Net loss for the year				-26,047,375		-26,047,375
Foreign currency translation adjustment					($643,221)	($643,221)
Balance, at Dec. 31, 2014	43,579,557	43,580	23,590,204	62,848,901	19,771,160	106,253,845

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash Flows from Operating Activities:
Net loss.	($26,047,375)	($20,008,049)
Depreciation and amortization	1,785,835	1,612,830
Bad debt expense.	20,643,035	10,752,991
Deferred income taxes	77,042	1,061,413
Inventory obsolescence reserve	-1,055,529	6,121,655
Changes in assets and liabilities:
Trade accounts and other receivables	-3,443,329	3,633,180
Advances to suppliers	-296,979	-2,625,629
Inventory	12,780,457	11,155,810
Trade accounts payable	634,673	-1,183,733
Accrued taxes payable	84	-2,499,949
Other payables and accrued expenses	37,584	356,640
Advances from customers	-139,066	218,656
Prepaid expenses	-404,060
Net Cash Provided by Operating Activities	4,572,372	8,595,815
Cash Flows from Investing Activities:
Advances for purchases of intangible assets	-714,697	-298,631
Purchases of property and equipment	-5,128,699	-18,794,261
Net Cash Used in Investing Activities	-5,843,396	-19,092,892
Cash Flows from Financing Activities:
Proceeds from construction term loan	605,002	12,322,648
Net Cash Provided by Financing Activity	605,002	12,322,648
Effect of Exchange Rate Changes on Cash	-31,327	137,860
Net (Decrease) Increase in Cash and Cash Equivalents	-697,349	1,963,431
Cash and Cash Equivalents at Beginning of Period	5,993,139	4,029,708
Cash and Cash Equivalents at End of Period	5,295,790	5,993,139
Supplemental Cash Flow Information:
Cash paid for interest	1,230,800	569,855
Cash paid for income taxes	0	2,481,164
Supplemental Noncash Investing and Financing Activities:
Accounts payable for purchases of property and equipment	46,780	144,243
Accounts receivable collected with banker's acceptances	2,777,579	8,317,045
Inventory purchased with banker's acceptances	2,489,698	4,626,165
Advances for purchases of equipment paid with banker's acceptances	0	2,564,790
Advances for purchases of intangibles paid with banker's acceptances	$164,208	$897,820

ORGANIZATION_AND_SIGNIFICANT_A

ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES
ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES
	Organization and Nature of Operations – China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical & Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People's Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.
	On December 31, 2012, China Pharma Holdings, Inc consummated a reincorporation merger for the purpose of changing its state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.  The reincorporation merger was approved by stockholders holding the majority of the Company’s outstanding shares of common stock on December 21, 2012.
	The Foreign Investment Industrial Catalogue (the “Catalogue”) jointly issued by China’s Ministry of Commerce and the National Development and Reform Commission (the latest version is the 2012 version, effective January 30, 2012) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the “FIE”) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case for the Company’s business.
	Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson’s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005 by entering into an Equity Transfer Agreement with Helpson’s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.
	The Company has acquired and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.
	Consolidation and Basis of Presentation – The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.
	Helpson’s functional currency is the Chinese Renminbi. Helpson’s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson’s financial statements are included in accumulated other comprehensive income, which is a component of stockholders’ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.
	Accounting Estimates - The methodology used to prepare for the Company’s financial statements is in conformity with the accounting principles generally accepted in the United States of America, which requires the management of the Company (“Management”) to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.
	Cash and Cash Equivalents – Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker’s acceptances purchased with maturities of three months or less.
	Trade Accounts Receivable and Allowance for Doubtful Accounts – Trade accounts receivables are carried at the original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company's customer base. The Company reviews a customer's credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. It is common practice in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts. As of December 31, 2014, the Company had trade accounts receivable amounting to $48,569,986 from sales that occurred more than one year from that date, which the Company believes are collectable.
	During 2014, the Company offered two of its largest customers a discount of 30% for payments for accounts receivable that were older than one year. The amount of the outstanding accounts receivable balance the discount was applied to was approximately $1.8 million. As a result, the Company recognized additional bad debt expense of approximately $0.53 million for the year ended December 31, 2014.  During 2013, Management negotiated settlement offers with certain customers with approximately $8.0 million in accounts receivable balances that were greater than one (1) year past due. The offers to these customers were comprised of discounts ranging from 15% to 30% of the total past due balance in exchange for payment in full by December 31, 2013. As a result, the Company was able to collect cash of approximately $5.85 million, and recognized additional bad debt expenses for the negotiated discounts of approximately $2.1 million for the year ended December 31, 2013.
	Advances to Suppliers and Advances from Customers – Common practice in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold.
	Inventory – Inventory is stated at the lower of cost or net realizable value, computed on an average cost basis. We charge inventory obsolescence expense for inventory allowance to write down our inventory to the lower of cost or estimated market value or to completely write off obsolete or excess inventory. Charges to inventory obsolescence expense totaled $2,250,130 and $9,881,711 for the years ended December 31, 2014 and 2013, respectively. The Company recognized an inventory obsolescence reserve of ($1,093,082) and $6,257,142 for the years ended December 31, 2014 and 2013, respectively.
	Valuation of Long-Lived Assets – The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. For the years ended December 31, 2014 and 2013, the Company evaluated its long-lived assets and determined that no impairment adjustment was necessary.
	Property and Equipment – Property and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition.
	Revenue Recognition – Revenue is considered earned when the Company obtains persuasive evidence of an arrangement with the customer, when delivery of the products has occurred, when the sales price is fixed or determinable, and when collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, the risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company obtains objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved.
	Cost of Revenues – Cost of revenues includes wages, materials, handling charges, and other expenses associated with the manufacture and delivery of products.
	Research and Development – Research and development expenditures are recorded as expenses in the period in which they occur. Research and development expenses were $2,798,557 and $1,683,244 for the years ended December 31, 2014 and 2013, respectively.
	Retirement Benefit Plans – The Company is required to make monthly contributions at prescribed rates to various employee retirement benefit plans organized by the provincial governments. The benefit plans of the government assume the retirement benefit obligations of all existing and future retired employees of the Company. The Company contributed $249,921 and $241,384 to retirement benefit plans for the years ended December 31, 2014 and 2013, respectively. Contributions to these plans are charged to expense as incurred.
	Advertising Costs – Advertising costs are expensed when incurred. The Company did not incur any advertising costs for the years ended December 31, 2014 and 2013.
	Basic and Diluted (Loss) Earnings per Common Share - Basic (loss) earnings per common share is computed by dividing net (loss) income by the weighted-average number of common shares outstanding during the period. Diluted (loss) earnings per share is calculated to give effect to potentially issuable dilutive common shares.
	The following table is a presentation of the numerators and denominators used in the calculation of basic and diluted (loss) earnings per share:
		For the Year
		Ended December 31,
		2014			2013
	Net loss	$	(26,047,375	)	$	(20,008,049	)
	Basic weighted-average common shares outstanding		43,579,557			43,579,557
	Effect of dilutive securities:
	Warrants		-			-
	Options		-			-
	Diluted weighted-average common shares outstanding		43,579,557			43,579,557
	Basic loss per share	$	(0.60	)	$	(0.46	)
	Diluted loss per share	$	(0.60	)	$	(0.46	)
	There were no potential dilutive common shares outstanding during the years ended December 31, 2014 and 2013, respectively.
	Credit Risk – The carrying amount of accounts receivable included in the balance sheet represents the Company's exposure to credit risk in relation to its financial assets. No other financial assets carries a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer's financial condition. The Company maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management's estimates.
	The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors’ interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June 1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company’s deposits may be at a higher risk of loss.
	Interest Rate Risk – The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.
	Recent Accounting Pronouncements
	In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers" (ASU 2014-09), which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. ASU 2014-09 will be effective for the Company’s fiscal year beginning January 1, 2017, with early application not permitted. The Company is in the process of determining what impact, if any, the adoption of ASU 2014-09 will have on its financial statements and related disclosures. The standard permits the use of either the full retrospective or modified retrospective transition method. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
	In June 2014, the FASB issued ASU 2014-12, Compensation-Stock Compensation (Topic 718). The ASU clarifies how entities should treat performance targets that can be achieved after the requisite service period of a share-based payment award. The accounting standard is effective for interim and annual periods beginning December 15, 2015.  The Company does not anticipate the adoption of ASU 2014-12 will have a material impact on its financial statements and related disclosures.
	Other accounting standards that have been issued by the FASB or other standards-setting bodies are not expected to have a material effect on the Company’s financial position, result of operations or cash flows.

LOSSES_FROM_NATURAL_DISASTER

LOSSES FROM NATURAL DISASTER	12 Months Ended
	Dec. 31, 2014
LOSSES FROM NATURAL DISASTER
LOSSES FROM NATURAL DISASTER	NOTE 2 – LOSSES FROM NATURAL DISASTER
	On July 18, 2014, the Company’s manufacturing facilities and inventory sustained storm damage from a powerful tropical typhoon that hit Haikou on that date. The losses are comprised of $2,016,068 of inventory related costs and $260,451 of facilities damage costs.  The Company received minor insurance compensation as only the building of new plant was insured and the damage to it was minor.
	The Company assessed whether any asset impairment had occurred as a result of the storm and decided no impairment necessary. In addition, the Company assessed whether the damage caused by the tropical typhoon exposed the Company to environmental remediation liability. Based on the assessment, the Company determined that no such exposure had occurred.

PRODUCT_RECALL

PRODUCT RECALL	12 Months Ended
	Dec. 31, 2014
PRODUCT RECALL
PRODUCT RECALL	NOTE 3 – PRODUCT RECALL
	In March 2013, the China Food and Drug Administration (“CFDA”) issued a nationwide notice (the “CFDA Notice”) for the cessation of the production, sale and use of Buflomedil effective immediately. The CFDA Notice was a result of its reevaluation on the indications from the recent China and international research materials. The CFDA found that the risks of side effects to the nervous system and the cardiovascular system from Buflomedil have surpassed its clinical treatment benefits. The CFDA Notice was applicable to all the manufacturers and distributers in China who are in the business of the production and sale of Buflomedil-related products.
	Pursuant to the CFDA Notice, the Company ceased the production and sale of Buflomedil-based products and ceased all promotional and marketing activities for Buflomedil-based products. Furthermore, the Company recognized an inventory obsolescence allowance of approximately $3.7 million for Buflomedil-related raw materials and finished goods inventory. This was recorded as inventory obsolescence on the accompanying statement of operations for the year ended December 31, 2013.
	In addition, the Company recalled Buflomedil-based products from the market. The Company authorized the return of its previously sold Buflomedil-related products through April 30, 2013. The loss from the refunds to customers was $27,507 and was recognized as a reduction of revenues for the year ended December 31, 2013. Under CFDA regulatory provisions, the CFDA notice does not impose legal liability to the manufacturers of Buflomedil as long as they act pursuant to the CFDA Notice to cease the production, sale and use of Buflomedil and destroy such finished goods immediately.
	Pursuant to the CFDA Notice, the CFDA revoked all production licenses for Buflomedil-based products. The carrying value of the Company’s Buflomedil-related intangible assets was zero; therefore, no impairment of the Company’s intangible assets was necessary.

INVENTORY

INVENTORY.	12 Months Ended
	Dec. 31, 2014
INVENTORY
INVENTORY	NOTE 4 – INVENTORY
	Inventory consisted of the following:
		December 31,			December 31,
		2014			2013
	Raw materials	$	18,819,570		$	28,259,707
	Work in process		-			853,602
	Finished goods		3,436,330			3,590,937
			22,255,900			32,704,246
	Obsolescence reserve		(6,934,044	)		(8,027,126	)
	Total Inventory	$	15,321,856		$	24,677,120

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2014
PROPERTY AND EQUIPMENT
PROPERTY AND EQUIPMENT	NOTE 5 - PROPERTY AND EQUIPMENT
	Property and equipment consisted of the following:
		December 31,			December 31,
		2014			2013
	Permit of land use	$	458,853		$	460,964
	Building		11,279,704			2,494,623
	Plant, machinery and equipment		28,358,694			6,671,620
	Motor vehicle		150,976			151,670
	Office equipment		268,521			229,210
	Construction in progress		5,848			25,497,600
	Total		40,522,596			35,505,687
	Less: accumulated depreciation		(6,640,718	)		(5,264,350	)
	Property and Equipment, net	$	33,881,878		$	30,241,337
	Construction in progress consists primarily of the construction of a new production facility, the acquisition of related equipment and capitalized interest during the construction period. Once the building and machinery is in production and the facility is in use, the amount of construction in progress is moved into plant, machinery and equipment and depreciated. During the year ended December 31, 2014, an aggregate of approximately $25.5 million was reclassified from construction in progress to their respective property and equipment category as the assets were placed in service and depreciation commenced. A reconciliation of total interest cost incurred to interest expense as recognized in the consolidated statement of operations is as follows:
		For the Year
		Ended December 31,
		2014			2013
	Total interest cost incurred	$	1,244,346		$	583,400
	Interest cost capitalized		458,542			234,704
	Interest expense	$	785,804		$	348,696
	Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:
	Asset	Life - years
	Permit of land use	40 - 70
	Building	20 - 49
	Plant, machinery and equipment	10-May
	Motor vehicle	10-May
	Office equipment	5-Mar
	Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. For the years ended December 31, 2014 and 2013, depreciation expense was $1,399,396 and $846,512, respectively.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2014
INTANGIBLE ASSETS
INTANGIBLE ASSETS	NOTE 6 - INTANGIBLE ASSETS
	Intangible assets represent the cost of medical formulas approved for production by the CFDA. The Company did not obtain CFDA production approval for any medical formula during the year ended December 31, 2014 and 2013 and no costs were reclassified from advances to intangible assets in 2014 and 2013, respectively.
	Approved medical formulas are amortized from the date CFDA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.  It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $386,440 and $766,318 for the years ended December 31, 2014 and 2013, respectively, and was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period.
	The Company evaluates each approved medical formula for impairment at the date of CFDA approval, when indications of impairment are present and at the date of each financial statement. The Company’s evaluation is based on an estimated undiscounted net cash flow model, considering currently available market data for the related drug and the Company’s estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment losses were recognized during the years ended December 31, 2014 and 2013, respectively.
	Intangible assets consisted solely of CFDA approved medical formulas as follows:
		December 31,			December 31,
		2014			2013
	Gross carrying amount	$	5,499,494		$	5,524,785
	Accumulated amortization		(4,182,273	)		(3,812,992	)
	Net carrying amount	$	1,317,221		$	1,711,793
	The estimated aggregate annual amortization expense for each of the next five years and thereafter is as follows:
	Year	Amount
	2015	$          321,753
	2016	300,191
	2017	258,094
	2018	137,930
	2019	64,755
	Thereafter	234,498
	Total	$       1,317,221

ADVANCES_FOR_PURCHASES_OF_INTA

ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.	12 Months Ended
	Dec. 31, 2014
ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS
ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.	NOTE 7 – ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS
	In order to expand the number of medicines the Company manufactured and marketed, it has entered into contracts with independent laboratories and others for the purchase of medical formulas. Although CFDA approval had not been obtained for these medical formulas at the dates of the respective contracts, the objective of the contracts is for the Company to purchase CFDA-approved medical formulas once the CFDA approval process is completed. The Company received the titles to two patents that relate to medical formulas currently in the CFDA approval process for the year end December 31, 2013. These patents have not expired.
	Prior to entering into contracts with the Company, laboratories typically are required to complete all  research and development to determine the content of the medical formula and the method to produce the generic medicine. The application to the CFDA for production approval must be made by the production facility that will produce the related product. As a result, a contract typically provides that the Company buys the medical formula from the laboratory and the laboratory is required to assist the Company in applying for and obtaining the production approval from the CFDA.
	A typical CFDA approval process for the production of a generic medical product involves a number of steps that generally require three to five years to complete. If the medical formula is purchased at the point when the generic medical product receives the CFDA’s approval for a clinical study, which is very typical for the Company, the clinical study that follows will usually take from one and a half to three years to complete. After completing the clinical study, the results are submitted to the CFDA and a production approval application is filed with the CFDA. In most cases, it will take between eight to eighteen months to prepare and submit the production approval application and obtain CFDA approval. Upon approving the generic medical product, the CFDA issues a production certificate and the Company can commence the production and sales of the generic medical product. As a result of this process, CFDA approval is expected to be received in approximately two to five years from the date  the Company signs the medical formula contracts.
	Under the terms of the contracts, the laboratories are required to assist the Company in obtaining production approval for the medical formulas from the CFDA. Management monitors the status of each medical formula on a regular basis in order to assess whether the laboratories are performing adequately under the contracts. If a medical product is not approved by the CFDA, as evidenced by their issuance of a denial letter, or if the laboratory breaches the contract, the laboratory is required under the contract to provide a refund to the Company of the full amount of the payments made to the laboratory for that formula, or the Company can require the application of those payments to another medical formula with the same laboratory. As a result of the refund right, the Company is ultimately purchasing an approved medical product. Accordingly, payments made prior to the issuance of production approval by the CFDA are recorded as advances for purchases of intangible assets.
	To date, no formula has failed to receive CFDA production approval nor has the Company been informed or become aware of any formula that may fail to receive such approval. However, there is no assurance that the medical products will receive production approval and if the Company does not receive such approval, it will enforce its contractual rights to receive the refund from the laboratory or have the payments applied to another medical formula with the same laboratory.
	As of December 31, 2014 and 2013, the Company was obligated to pay laboratories and others approximately $4,551,000 and $5,466,000, respectively, upon the completion of the various phases of contracts to obtain CFDA production approval of medical formulas.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2014
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	NOTE 8 – RELATED PARTY TRANSACTIONS
	A member of the Company’s board of directors had previously advanced the Company an aggregate amount of $1,354,567 as of December 31, 2014 and 2013 which are recorded as other payables – related parties on the accompanying consolidated balance sheets. The advances bear interest at a rate of 1.0% per year.  Total interest expense of $13,546 was recognized for each of the years ended December 31, 2014 and 2013.

NOTES_PAYABLE

NOTES PAYABLE	12 Months Ended
	Dec. 31, 2014
NOTES PAYABLES
NOTES PAYABLES	NOTE 9 – NOTES PAYABLE
	On October 30, 2012, the Company entered into a revolving line of credit with a bank in the amount of RMB 30,000,000. The related note payable bore interest at an annual rate of 6.90% (based upon 115% of the PRC government’s current short term rate of 6.00%). Advances on the line of credit were due one year from the date of the advance and were collateralized by certain land use rights, buildings and accounts receivable. On November 1, 2013 the Company entered into a new revolving line of credit for the same amount with the same bank.  Advances on the line of credit are due one year from the date of the advance and are collateralized by certain land use rights, buildings and accounts receivable and bear interest at an annual rate of 6.6% (based upon 110% of the PRC government’s current short term rate of 6.00%).  In addition, the Company’s Chief Executive Officer and Chair of the board of directors personally guaranteed the new line of credit.
	In November 2014, the Company entered into a new line of credit with the same bank on identical terms.  The amounts advanced under the line of credit are due November 24, 2015. Advances on the line of credit are due one year from the date of the advance and are collateralized by certain land use rights, buildings and accounts receivable and bear interest at an annual rate of 6.16% (based upon 110% of the PRC government’s current short term rate of 5.6%). In addition, the Company’s Chief Executive Officer and Chair of the board of directors personally guaranteed the new line of credit.
	The outstanding balance due under the revolving line of credit was RMB 30,000,000 as of December 31, 2014 and 2013 ($4,887,187 as of December 31, 2014 and $4,909,662 as of December 31, 2013).  The Company has no additional amounts available to it under this line of credit.  This amount has been classified as short-term notes payable in the accompanying consolidated balance sheets as of December 31, 2014 and 2013.
	Fair Value of Notes Payable – Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of notes payable outstanding as of December 31, 2014 and 2013 approximated their fair value because of the immediate or short-term maturity of these financial instruments and because the underlying instruments bear interest rates that approximated current market rates.

CONSTRUCTION_LOAN_FACILITY

CONSTRUCTION LOAN FACILITY.	12 Months Ended
	Dec. 31, 2014
CONSTRUCTION LOAN FACILITY
CONSTRUCTION LOAN FACILITY
	NOTE 10 – CONSTRUCTION LOAN FACILITY
	The Company obtained a construction loan facility in the amount of RMB 80,000,000 (approximately $13.0 and $12.5 million as of December 31, 2014 and 2013, respectively) from a construction loan facility dated June 21, 2013. The loan facility is for an eight-year term, which commenced on July 11, 2013, the initial draw-down date. The total loan facility amount is RMB 80,000,000 (approximately $13 million) and is from the same bank that currently provides the line of credit as discussed in Note 9.  The proceeds of the loan were used for and are collateralized by the construction of the Company’s new production facility and the included production line equipments and machinery. The loan currently bears interest at 7.205%, based upon 110% of the PRC government’s eight-year term rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates.  The loan requires interest only payments for the first two years. Beginning July 11, 2015, the balance of the principal is due in annual installments over the next six years through July 11, 2021. As of December 31, 2014, the Company had no additional amounts available to it under this loan facility.
	Principal payments required for the next five years as of December 31, 2014 are as follows:
	Year	Amount
	2015		1,629,062
	2016		1,629,062
	2017		2,443,594
	2018		2,443,594
	2019		2,443,594
	Thereafter		2,443,594
		$	13,032,500
	Fair Value of Construction Loan Facility – Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of the construction loan facility outstanding as of December 31, 2014 approximated its fair value because the underlying instrument bears an interest rate that approximated current market rates.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2014
INCOME TAXES
INCOME TAXES	NOTE 11 - INCOME TAXES
	Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax laws or rates is recognized in income in the period that includes the enactment date.
	Undistributed earnings of Helpson, the Company’s foreign subsidiary, since its acquisition, amounted to approximately $68.3 million as of December 31, 2014. Those earnings, as well as the investment in Helpson of approximately $23.3 million, are considered to be indefinitely reinvested and, accordingly, no U.S. federal or state income taxes have been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, the Company would be subject to U.S. federal and state income taxes (net of an adjustment for foreign tax credits) and withholding taxes payable to the PRC. Determination of the amount of unrecognized deferred U.S. income tax liability is not practical because of the complexities associated with its hypothetical calculation; however, unrecognized foreign tax credits may be available to reduce a portion of the U.S. tax liability.
	Liabilities are established for uncertain tax positions expected to be taken in income tax return when such positions are judged to meet the “more-likely-than-not” threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a component of other expenses. Through December 31, 2014, the Company has not identified any uncertain tax positions that it has taken. U.S. income tax returns for the years ended December 31, 2011 through December 31, 2014 and the Chinese income tax return for the year ended December 31, 2014 are open for possible examination.
	On March 16, 2007, the National People’s Congress of China passed the Enterprise Income Tax Law (EIT Law) and on December 6, 2007, the State Council of China issued the Implementation Regulations for the EIT Law which took effect on January 1, 2008. The EIT Law and Implementation Regulations Rules impose a unified EIT of 25% on all domestic-invested enterprises and Foreign Invested Entities, or FIEs, unless they qualify under certain limited exceptions.
	The Company is located in a special region, which had a 15% corporate income tax rate before the new EIT Law. The new EIT Law abolished the preferential corporate income tax rate in the special region. The Company transitioned to the new 25% tax rate over a five year period which began on January 1, 2008. During 2010, the Company applied for and received a favorable tax rate of 15% for fiscal 2011 through 2013 due to its status in the PRC as a high technology enterprise. In 2013, the Company again applied for and received the same favorable tax rate for 2014 to 2016.  Under the current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:
		Enterprise Income
	Year	Tax Rate
	2013	15%
	2014	15%
	2015	15%
	2016	15%
	2017	25%
	Thereafter	25%
	The provision for income taxes consisted of the following:
		Year Ended December 31,
		2014			2013
	Current	$	-		$	-
	Deferred		77,042			1,061,413
	Total income tax expense (benefit)	$	77,042		$	1,061,413
	Following is a reconciliation of income taxes calculated at the federal statutory rates to the provision for income taxes:
		Years Ended December 31,
		2014			2013
	(Benefit) tax at statutory rate of 25%	$	(6,511,844	)	$	(4,736,660	)
	Stock based compensation from current and prior years		-			8,534
	Effect of tax holiday		2,563,701			1,834,517
	Other, primarily the difference in U.S. tax rates		7,815			-
	Change in valuation allowance		4,017,370			3,955,022
	Income tax expense	$	77,042		$	1,061,413
	The effect of the tax holiday amounted to a change in the tax expense (benefit) of $2,559,466 and $1,834,517 for the years ended December 31, 2014 and 2013, which was equivalent to basic and diluted earnings per share of ($0.09) and ($0.04) per share for the years ended December 31, 2014 and 2013, respectively. The temporary differences which give rise to the deferred income tax assets and liability are as follows:
		December 31,
		2014			2013
	Deferred income tax assets:
	Allowance for doubtful trade receivables	$	5,002,516		$	1,995,243
	Allowance for doubtful other receivables		9,049			6,460
	Inventory obsolescence reserve		1,040,107			1,501,687
	Expenses not deductible in current year		31,000			31,143
	PRC net operating loss carry forward		1,688,417			328,643
	U.S. net operating loss carry forward		1,181,679			1,052,784
	Total deferred income tax assets		8,952,768			4,915,960
	Valuation allowance		(8,952,768	)		(4,915,960	)
	Net deferred income tax asset	$	-		$	-
	Deferred income tax liability:
	Intangible assets	$	252,707		$	176,414
	As of December 31, 2014, the Company had net operating loss carryforwards for PRC tax purposes of approximately $11.3 million which are available to offset any future taxable income through 2019. The Company also has net operating losses for United States federal income tax purposes of approximately $3.5 million which are available to offset future taxable income, if any, through 2034.
	In assessing the realizability of deferred tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.  The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized.  Management considers projected future taxable income and tax planning strategies in making this assessment.  Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, Management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of December 31, 2014 and 2013.  Therefore, the Company provided for a valuation allowance against its deferred tax assets of $8,952,768 and $4,915,960 as of December 31, 2014 and 2013, respectively.
	The Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2014
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS	NOTE 12 – FAIR VALUE MEASUREMENTS
	Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data. Level 3 – Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.
	The Company uses fair value to measure the derivative warrant liability on a recurring basis because fair value is the primary measure for accounting. The Company also uses fair value to measure the value of the banker’s acceptance notes it holds.  The Company values its derivative warrants using a valuation method explained above.  The banker’s acceptance notes are recorded at cost which approximates fair value.  The Company held the following assets and liabilities recorded at fair value as of December 31, 2014 and 2013:
				Fair Value Measurements at
				Reporting Date Using
	Description	31-Dec-14		Level 1		Level 2		Level 3
	Banker's acceptance notes	$	458,233	$	-	$	458,233	$	-
	Total	$	458,233	$	-	$	458,233	$	-
				Fair Value Measurements at
				Reporting Date Using
	Description	31-Dec-13		Level 1		Level 2		Level 3
	Banker's acceptance notes	$	336,003	$	-	$	336,003	$	-
	Total	$	336,003	$	-	$	336,003	$	-

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2014
STOCKHOLDERS' EQUITY
STOCKHOLDERS' EQUITY	NOTE 13 - STOCKHOLDERS' EQUITY
	The Company is authorized to issue 95,000,000 shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company’s board of directors.
	Warrants
	As of December 31, 2012, the Company had warrants outstanding and exercisable to purchase an aggregate of 150,000 shares of Company's common stock at exercise prices ranging from $3.00 to $3.80 per share, which expired on May 16, 2013.As of December 31, 2014 and 2013, the Company had no warrants outstanding.
	Employee Stock Options
	2010 Incentive Plan
	On November 12, 2010, the Company’s Board of Directors adopted the Company’s 2010 Incentive Plan (the “Plan”), which was then approved by stockholders on December 22, 2010. The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 4,000,000 shares of common stock. Through December 31, 2014, there were 175,000 shares of restricted stock granted and outstanding under the Plan.  No options were outstanding as of December 31, 2014 under the Plan.
	There were no securities issued from the Plan during each of the year ended December 31, 2014 and 2013.  Options to purchase 25,000 shares of common stock at an exercise price of $2.54 per share were forfeited during 2013.
	The Company recognized no compensation expense related to the awards of common shares and the grants and modifications of stock options during each of the years ended December 31, 2014 and 2013.
	The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model. Expected volatility is based on the historical volatility of the Company’s common stock prices. The Company uses historical data to estimate employee termination rates. The expected term of options granted is determined by the simplified method, which is one-half of the original contractual term. The simplified method is used due to the lack of historical share option exercise data to provide a reasonable basis upon which to estimate expected term. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.
	As of December 31, 2014, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2014
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	NOTE 14 – COMMITMENTS AND CONTINGENCIES
	Economic environment - Substantially all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with companies operating in the United States of America. These risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company's results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect the Company’s operations.
	In addition, all of the Company's revenue is denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.
	Contractual Commitments – The Company entered into purchase and construction agreements during the year ended December 31, 2013 in connection with the construction of a new facility and required manufacturing improvements.  Under these agreements, the Company made payments in the amount of $4,637,671 and $25,474,525 during the years ended December 31, 2014 and 2013, respectively. These payments are classified as property and equipment as of December 31, 2014 and as construction in progress on the accompanying balance sheet as of December 31, 2013.

CONCENTRATIONS

CONCENTRATIONS	12 Months Ended
	Dec. 31, 2014
CONCENTRATIONS
CONCENTRATIONS	NOTE 15 – CONCENTRATIONS
	For the year ended December 31, 2014, one customer accounted for 16.2% of sales and one supplier accounted for 26.5% of raw material purchases, one customer accounted for 17.7% of accounts receivable, and three different products accounted for 49%, 12% and 11% of revenue.
	For the year ended December 31, 2013, no customer accounted for more than 10% of sales and one supplier accounted for 18.7% of raw material purchases, two customers accounted for 14.5% and 11.2% of accounts receivable, and three different products accounted for 35%, 13% and 10% of revenue.

Accounting_Policies_Policies

Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies (Policies)
Organization and Nature of Operations	Organization and Nature of Operations – China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical & Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People's Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.
	On December 31, 2012, China Pharma Holdings, Inc consummated a reincorporation merger for the purpose of changing its state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.  The reincorporation merger was approved by stockholders holding the majority of the Company’s outstanding shares of common stock on December 21, 2012.
	The Foreign Investment Industrial Catalogue (the “Catalogue”) jointly issued by China’s Ministry of Commerce and the National Development and Reform Commission (the latest version is the 2012 version, effective January 30, 2012) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the “FIE”) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case for the Company’s business.
	Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson’s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005 by entering into an Equity Transfer Agreement with Helpson’s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.
	The Company has acquired and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.
Consolidation and Basis of Presentation	Consolidation and Basis of Presentation – The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.
	Helpson’s functional currency is the Chinese Renminbi. Helpson’s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson’s financial statements are included in accumulated other comprehensive income, which is a component of stockholders’ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.
Accounting Estimates	Accounting Estimates - The methodology used to prepare for the Company’s financial statements is in conformity with the accounting principles generally accepted in the United States of America, which requires the management of the Company (“Management”) to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.
Cash and Cash Equivalents, Policy	Cash and Cash Equivalents – Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker’s acceptances purchased with maturities of three months or less.
Trade Accounts Receivable and Allowance for Doubtful Accounts	Trade Accounts Receivable and Allowance for Doubtful Accounts – Trade accounts receivables are carried at the original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company's customer base. The Company reviews a customer's credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. It is common practice in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts. As of December 31, 2014, the Company had trade accounts receivable amounting to $48,569,986 from sales that occurred more than one year from that date, which the Company believes are collectable.
	During 2014, the Company offered two of its largest customers a discount of 30% for payments for accounts receivable that were older than one year. The amount of the outstanding accounts receivable balance the discount was applied to was approximately $1.8 million. As a result, the Company recognized additional bad debt expense of approximately $0.53 million for the year ended December 31, 2014.  During 2013, Management negotiated settlement offers with certain customers with approximately $8.0 million in accounts receivable balances that were greater than one (1) year past due. The offers to these customers were comprised of discounts ranging from 15% to 30% of the total past due balance in exchange for payment in full by December 31, 2013. As a result, the Company was able to collect cash of approximately $5.85 million, and recognized additional bad debt expenses for the negotiated discounts of approximately $2.1 million for the year ended December 31, 2013.
Advances to Suppliers and Advances from Customers	Advances to Suppliers and Advances from Customers – Common practice in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold.
Inventory, Policy	Inventory – Inventory is stated at the lower of cost or net realizable value, computed on an average cost basis. We charge inventory obsolescence expense for inventory allowance to write down our inventory to the lower of cost or estimated market value or to completely write off obsolete or excess inventory. Charges to inventory obsolescence expense totaled $2,250,130 and $9,881,711 for the years ended December 31, 2014 and 2013, respectively. The Company recognized an inventory obsolescence reserve of ($1,093,082) and $6,257,142 for the years ended December 31, 2014 and 2013, respectively.
Valuation of Long-Lived Assets	Valuation of Long-Lived Assets – The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. For the years ended December 31, 2014 and 2013, the Company evaluated its long-lived assets and determined that no impairment adjustment was necessary.
Property, Plant and Equipment, Policy	Property and Equipment – Property and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition.
Revenue Recognition, Policy	Revenue Recognition – Revenue is considered earned when the Company obtains persuasive evidence of an arrangement with the customer, when delivery of the products has occurred, when the sales price is fixed or determinable, and when collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, the risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company obtains objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved.
Cost of Revenues, Policy	Cost of Revenues – Cost of revenues includes wages, materials, handling charges, and other expenses associated with the manufacture and delivery of products.
Research and Development Expense, Policy	Research and Development – Research and development expenditures are recorded as expenses in the period in which they occur. Research and development expenses were $2,798,557 and $1,683,244 for the years ended December 31, 2014 and 2013, respectively.
Retirement Benefit Plans	Retirement Benefit Plans – The Company is required to make monthly contributions at prescribed rates to various employee retirement benefit plans organized by the provincial governments. The benefit plans of the government assume the retirement benefit obligations of all existing and future retired employees of the Company. The Company contributed $249,921 and $241,384 to retirement benefit plans for the years ended December 31, 2014 and 2013, respectively. Contributions to these plans are charged to expense as incurred.
Advertising Costs, Policy	Advertising Costs – Advertising costs are expensed when incurred. The Company did not incur any advertising costs for the years ended December 31, 2014 and 2013.
Basic and Diluted (Loss) Earnings per Common Share	Basic and Diluted (Loss) Earnings per Common Share - Basic (loss) earnings per common share is computed by dividing net (loss) income by the weighted-average number of common shares outstanding during the period. Diluted (loss) earnings per share is calculated to give effect to potentially issuable dilutive common shares.
	The following table is a presentation of the numerators and denominators used in the calculation of basic and diluted (loss) earnings per share:
		For the Year
		Ended December 31,
		2014			2013
	Net loss	$	(26,047,375	)	$	(20,008,049	)
	Basic weighted-average common shares outstanding		43,579,557			43,579,557
	Effect of dilutive securities:
	Warrants		-			-
	Options		-			-
	Diluted weighted-average common shares outstanding		43,579,557			43,579,557
	Basic loss per share	$	(0.60	)	$	(0.46	)
	Diluted loss per share	$	(0.60	)	$	(0.46	)
	There were no potential dilutive common shares outstanding during the years ended December 31, 2014 and 2013, respectively.
Credit Risk, Policy	Credit Risk – The carrying amount of accounts receivable included in the balance sheet represents the Company's exposure to credit risk in relation to its financial assets. No other financial assets carries a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer's financial condition. The Company maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management's estimates.
	The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors’ interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June 1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company’s deposits may be at a higher risk of loss.
Interest Rate Risk	Interest Rate Risk – The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.
Recently Announced Accounting Standards
	Recent Accounting Pronouncements
	In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers" (ASU 2014-09), which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. ASU 2014-09 will be effective for the Company’s fiscal year beginning January 1, 2017, with early application not permitted. The Company is in the process of determining what impact, if any, the adoption of ASU 2014-09 will have on its financial statements and related disclosures. The standard permits the use of either the full retrospective or modified retrospective transition method. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
	In June 2014, the FASB issued ASU 2014-12, Compensation-Stock Compensation (Topic 718). The ASU clarifies how entities should treat performance targets that can be achieved after the requisite service period of a share-based payment award. The accounting standard is effective for interim and annual periods beginning December 15, 2015.  The Company does not anticipate the adoption of ASU 2014-12 will have a material impact on its financial statements and related disclosures.
	Other accounting standards that have been issued by the FASB or other standards-setting bodies are not expected to have a material effect on the Company’s financial position, result of operations or cash flows.

BASIS_OF_PRESENTATION_Tables

BASIS OF PRESENTATION (Tables)	12 Months Ended
	Dec. 31, 2014
BASIS OF PRESENTATION (Tables)
Presentation of the numerators and denominators used in the calculation of basic and diluted earnings per share	The following table is a presentation of the numerators and denominators used in the calculation of basic and diluted (loss) earnings per share:
		For the Year
		Ended December 31,
		2014			2013
	Net loss	$	(26,047,375	)	$	(20,008,049	)
	Basic weighted-average common shares outstanding		43,579,557			43,579,557
	Effect of dilutive securities:
	Warrants		-			-
	Options		-			-
	Diluted weighted-average common shares outstanding		43,579,557			43,579,557
	Basic loss per share	$	(0.60	)	$	(0.46	)
	Diluted loss per share	$	(0.60	)	$	(0.46	)

INVENTORYTables

INVENTORY(Tables)	12 Months Ended
	Dec. 31, 2014
INVENTORY (Tables)
Inventory consists	Inventory consisted of the following:
		December 31,			December 31,
		2014			2013
	Raw materials	$	18,819,570		$	28,259,707
	Work in process		-			853,602
	Finished goods		3,436,330			3,590,937
			22,255,900			32,704,246
	Obsolescence reserve		(6,934,044	)		(8,027,126	)
	Total Inventory	$	15,321,856		$	24,677,120

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2014
PROPERTY AND EQUIPMENT (Tables)
Property and equipment consists	Property and equipment consisted of the following:
		December 31,			December 31,
		2014			2013
	Permit of land use	$	458,853		$	460,964
	Building		11,279,704			2,494,623
	Plant, machinery and equipment		28,358,694			6,671,620
	Motor vehicle		150,976			151,670
	Office equipment		268,521			229,210
	Construction in progress		5,848			25,497,600
	Total		40,522,596			35,505,687
	Less: accumulated depreciation		(6,640,718	)		(5,264,350	)
	Property and Equipment, net	$	33,881,878		$	30,241,337
A reconciliation of total interest cost incurred to interest expense	. A reconciliation of total interest cost incurred to interest expense as recognized in the consolidated statement of operations is as follows:
		For the Year
		Ended December 31,
		2014			2013
	Total interest cost incurred	$	1,244,346		$	583,400
	Interest cost capitalized		458,542			234,704
	Interest expense	$	785,804		$	348,696
Useful lives of the assets	Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:
	Asset	Life - years
	Permit of land use	40 - 70
	Building	20 - 49
	Plant, machinery and equipment	10-May
	Motor vehicle	10-May
	Office equipment	5-Mar

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2014
Intangible Assets (Tables)
Intangible Assets Medical Formulas	Intangible assets consisted solely of CFDA approved medical formulas as follows:
		December 31,			December 31,
		2014			2013
	Gross carrying amount	$	5,499,494		$	5,524,785
	Accumulated amortization		(4,182,273	)		(3,812,992	)
	Net carrying amount	$	1,317,221		$	1,711,793
Estimated aggregate annual amortization expense	The estimated aggregate annual amortization expense for each of the next five years and thereafter is as follows:
	Year	Amount
	2015	$          321,753
	2016	300,191
	2017	258,094
	2018	137,930
	2019	64,755
	Thereafter	234,498
	Total	$       1,317,221

Schedule_of_Longterm_Debt_Inst

Schedule of Long-term Debt Instruments (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Long-term Debt Instruments:
Schedule of Long-term Debt Instruments	Principal payments required for the next five years as of December 31, 2014 are as follows:
	Year	Amount
	2015		1,629,062
	2016		1,629,062
	2017		2,443,594
	2018		2,443,594
	2019		2,443,594
	Thereafter		2,443,594
		$	13,032,500

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2014
INCOME TAXES (Tables)
Current Taxes	Under the current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:
		Enterprise Income
	Year	Tax Rate
	2013	15%
	2014	15%
	2015	15%
	2016	15%
	2017	25%
	Thereafter	25%
Provision For Income Taxes	The provision for income taxes consisted of the following:
		Year Ended December 31,
		2014			2013
	Current	$	-		$	-
	Deferred		77,042			1,061,413
	Total income tax expense (benefit)	$	77,042		$	1,061,413
Schedule of Income Tax Rate Reconciliation	Following is a reconciliation of income taxes calculated at the federal statutory rates to the provision for income taxes:
		Years Ended December 31,
		2014			2013
	(Benefit) tax at statutory rate of 25%	$	(6,511,844	)	$	(4,736,660	)
	Stock based compensation from current and prior years		-			8,534
	Effect of tax holiday		2,563,701			1,834,517
	Other, primarily the difference in U.S. tax rates		7,815			-
	Change in valuation allowance		4,017,370			3,955,022
	Income tax expense	$	77,042		$	1,061,413
Schedule of Deferred Tax Assets and Liabilities	The temporary differences which give rise to the deferred income tax assets and liability are as follows:
		December 31,
		2014			2013
	Deferred income tax assets:
	Allowance for doubtful trade receivables	$	5,002,516		$	1,995,243
	Allowance for doubtful other receivables		9,049			6,460
	Inventory obsolescence reserve		1,040,107			1,501,687
	Expenses not deductible in current year		31,000			31,143
	PRC net operating loss carry forward		1,688,417			328,643
	U.S. net operating loss carry forward		1,181,679			1,052,784
	Total deferred income tax assets		8,952,768			4,915,960
	Valuation allowance		(8,952,768	)		(4,915,960	)
	Net deferred income tax asset	$	-		$	-
	Deferred income tax liability:
	Intangible assets	$	252,707		$	176,414

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2014
FAIR VALUE MEASUREMENTS (Tables)
Assets Fair Value	The Company held the following assets and liabilities recorded at fair value as of December 31, 2014 and 2013:
				Fair Value Measurements at
				Reporting Date Using
	Description	31-Dec-14		Level 1		Level 2		Level 3
	Banker's acceptance notes	$	458,233	$	-	$	458,233	$	-
	Total	$	458,233	$	-	$	458,233	$	-
				Fair Value Measurements at
				Reporting Date Using
	Description	31-Dec-13		Level 1		Level 2		Level 3
	Banker's acceptance notes	$	336,003	$	-	$	336,003	$	-
	Total	$	336,003	$	-	$	336,003	$	-

BASIS_OF_PRESENTATION_Details

BASIS OF PRESENTATION (Details)	Dec. 31, 2014
Organization and operations
Percentage of share owned by China Pharma Holdings Inc of Onny Investment Limited	100.00%
Percentage of share owned by China Pharma Holdings Inc of Helpson Medical & Biotechnology Co., Ltd.	100.00%
Percetage of acquired by Onny in Helpson	100.00%

BASIS_OF_PRESENTATION_Basic_an

BASIS OF PRESENTATION Basic and Diluted Earnings per Common Share (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
BASIS OF PRESENTATION Basic and Diluted Earnings per Common Share
Net loss	($26,047,375)	($20,008,049)
Basic weighted-average common shares outstanding	43,579,557	43,579,557
Diluted weighted-average common shares outstanding	43,579,557	43,579,557
Basic loss per share	($0.60)	($0.46)
Diluted loss per share	($0.60)	($0.46)

BASIS_OF_PRESENTATION_POLICIES

BASIS OF PRESENTATION POLICIES Parentheticals (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Parentheticals - Trade Receivables
Accounts Receivable from sales	$48,569,986
Management negotiated settlement offers with certain customers in accounts receivable balances that were greater than one (1) year past due.	8,000,000
Amount collected in cash	5,850,000
Recognized additional bad debt expense for the negotiated discounts in the amount of	530,000	2,100,000
Charges to inventory obsolescence expense totalled to	2,250,130	9,881,711
Recognized inventory obsolescence reserve of	-1,093,082	6,257,142
Recognized impairment loss on intangible assets		593,095
Research and development expenses	2,798,557	1,683,244
Amount contributed to retirement benefit plans for the period	$249,921	$241,384

Losses_from_natural_disaster_D

Losses from natural disaster (Details) (USD $)	Jul. 18, 2014
Losses from natural disaster consists of
Company's manufacturing facilities and inventory sustained storm damage of inventory related costs	$2,016,068
Company's manufacturing facilities and inventory sustained storm damage of of facilities damage costs	$260,451

PRODUCT_RECALL_DETAILS

PRODUCT RECALL (DETAILS) (USD $)	12 Months Ended
	Dec. 31, 2014
PRODUCT RECALL
Recognized inventory obsolescence allowance of approx. For Buflomedil-related rawmaterials and finished goods inventory	$3,700,000
Loss from the refunds to customers	$27,507

Inventory_consisted_of_the_fol

Inventory consisted of the following (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Inventory consisted of the following
Raw materials	$18,819,570	$28,259,707
Work in process		853,602
Finished goods	3,436,330	3,590,937
Inventory Gross	22,255,900	32,704,246
Obsolescence reserve	-6,934,044	-8,027,126
Total Inventory	$15,321,856	$24,677,120

Property_and_equipment_consist

Property and equipment consisted of the following (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property and equipment consisted of the following
Permit of land use	$458,853	$460,964
Building	11,279,704	2,494,623
Plant, machinery and equipment	28,358,694	6,671,620
Motor vehicle	150,976	151,670
Office equipment	268,521	229,210
Construction in progress	5,848	25,497,600
Total Property and Equipment	40,522,596	35,505,687
Less: accumulated depreciation details	-6,640,718	-5,264,350
Property and Equipment, net;	$33,881,878	$30,241,337

INVENTORY_Details

INVENTORY. (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
INVENTORY ABSTRACT
Raw materials	$18,819,570	$28,259,707
Finished goods	3,436,330	3,590,937
Inventory Gross	$22,255,900	$32,704,246

PROPERTY_AND_EQUIPMENT_Details

PROPERTY AND EQUIPMENT (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
PROPERTY AND EQUIPMENT {2}
Permit of land use	$458,853	$460,964
Building	11,279,704	2,494,623
Plant, machinery and equipment	28,358,694	6,671,620
Motor vehicle	150,976	151,670
Office equipment	268,521	229,210
Construction in progress	5,848	25,497,600
Total Property and Equipment	40,522,596	35,505,687
Less: accumulated depreciation details	-6,640,718	-5,264,350
Property and Equipment, net	$33,881,878	$30,241,337

PROPERTY_AND_EQUIPMENT_Assets_

PROPERTY AND EQUIPMENT Assets Life (Details)	Dec. 31, 2014
PROPERTY AND EQUIPMENT Assets Life
Permit of land use minimum life	40
Permit of land use maximum life	70
Building minimum life	20
Building maximum life	49
Plant, machinery and equipment minimum life	5
Plant, machinery and equipment maximum life	10
Motor vehicle minimum life	5
Motor vehicle maximum life	10
Office equipment minimum life	3
Office equipment maximum life	5

Reconciliation_of_Total_Intere

Reconciliation of Total Interest incurred cost (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Reconcialition of Total interest details
Total interest cost incurred	$1,244,346	$583,400
Interest cost capitalized	458,542	234,704
Interest expense,	$785,804	$348,696

ASSETS_Depreciation_Details

ASSETS Depreciation (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Assets Depreciation
Depreciation Expense property and equipment	$1,399,396	$846,512

INTANGIBLE_ASSETS_CFDA_Approve

INTANGIBLE ASSETS CFDA Approved Medical Formulas (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
INTANGIBLE ASSETS CFDA Approved Medical Formulas
Gross carrying amount	$5,499,494	$5,524,785
Accumulated amortization Intangible assets SFDA Approved Medical Formulas	-4,182,273	-3,812,992
Net carrying amount	$1,317,221	$1,711,793

Estimated_Aggregate_Annual_Amo

Estimated Aggregate Annual Amortization expense for next five years and thereafter (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Estimated Aggregate Annual Amortization expense for next five years and thereafter
Annual amortization 2015	$321,753
Annual amortization 2016	300,191
Annual amortization 2017	258,094
Annual amortization 2018	137,930
Annual amortization 2019	64,755
Annual amortization Thereafter	234,498
Accumulated amortization Intangible assets CFDA Approved Medical Formulas	1,317,221
Impairment losses relating to those intangible assets	0	0
Amortization expenses relating to intangible asets was	$386,440	$766,318

ADVANCES_FOR_PURCHASES_OF_INTA1

ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Advances for purchase of intangible assets details
Company was obligated to pay laboratories	$4,551,000	$5,466,000

RELATED_PARTY_TRANSACTIONS_Mem

RELATED PARTY TRANSACTIONS Member Of BOD (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
RELATED PARTY TRANSACTIONS Member Of BOD
Total interest expense recognized for the period	$13,546	$13,546
Interest rate on advances from Member of BOD	1.00%	1.00%

RELATED_PARTY_TRANSACTIONS_Owi

RELATED PARTY TRANSACTIONS Owings (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
RELATED PARTY TRANSACTIONS Owings
Adavances owing to board member	$1,354,567	$1,354,567

NOTES_PAYABLES_Details

NOTES PAYABLES. (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
NOTES PAYABLES
Revolving line of credit with a bank (RMB)	$30,000,000
Annual interest rate	6.90%
Outstanding balance due under revolving line of credit (RMB 30,000,000)	$4,887,187	$4,909,662

CONSTRUCTION_LOAN_FACILITY_Det

CONSTRUCTION LOAN FACILITY (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Construction loan facility details
Total loan facility amount (RMB 80,000,)000	$13,000,000	$12,500,000
Loan interest	7.21%	7.21%

Principal_payments_required_fo

Principal payments required for the next five years as of December 31, 2014 are as follows: (Details) (USD $)	Dec. 31, 2014
Principal payments required for the next five years as of December 31, 2013 are as follows:
Principal Payments 2015	$1,629,062
Principal Payments 2016	1,629,062
Principal Payments 2017	2,443,594
Principal Payments 2018	2,443,594
Principal Payments 2019	2,443,594
Principal Payments Thereafter	2,443,594
Total principal payments due	$13,032,500

INCOME_TAXES_Undistributed_Ear

INCOME TAXES Undistributed Earnings And Income Tax Rates (Details) (USD $)	Dec. 31, 2014
INCOME TAXES Undistributed Earnings
Undistributed earnings of Helpson	$94,000,000
Investment in Helpson, a foreign subsidiary for the company	23,300,000
Enterprise Income Tax Rates for the year 2013	15.00%
Enterprise Income Tax Rates for the year 2014	15.00%
Enterprise Income Tax Rates for the year 2015	15.00%
Enterprise Income Tax Rates for the year 2016	15.00%
Enterprise Income Tax Rates for the year 2016 There after	25.00%
Net operating loss carryforwards for PRC tax purposes	11,300,000
Net operating loss carryforwards for US Federal income tax purposes	$3,500,000

INCOME_TAXES_Provision_Details

INCOME TAXES Provision (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
INCOME TAXES Provision
Current tax provision.	$0	$0
Deferred tax provision.	77,042	1,061,413
Total income tax expense	77,042	1,061,413
Effect of tax holiday amounted to a change in the tax expense (benefit) of	$2,559,466	$1,834,517
Equivalent to basic and diluted earnings per share of	($0.09)	($0.04)

Reconciliation_of_income_taxes

Reconciliation of income taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Reconciliation of income taxes
Tax at statutory rate of 25%	($6,511,844)	($4,736,660)
Current and prior years		8,534
Effect of tax holiday	2,563,701	1,834,517
Other, primarily the effect of US tax rates	7,815	0
Change in valuation allowance Reconciliation	4,017,370	3,955,022
Income tax expense Reconciliation	$77,042	$1,061,413

Changes_of_deferred_income_tax

Changes of deferred income tax assets and liability (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Changes of deferred income tax assets and liability
Allowance for doubtful trade receivables deferred tax	$5,002,516	$1,995,243
Allowance for doubtful other receivables deferred tax	9,049	6,460
Inventory obsolescence reserve	1,040,107	1,501,687
Expenses not deductible in current year	31,000	31,143
PRC Net operating loss carry forward	1,688,417	328,643
U.S. net operating loss carry forwards	1,181,679	1,052,784
Total deferred income tax assets	8,952,768	4,915,960
Valuation allowance,	-8,952,768	-4,915,960
Net deferred income tax asset.		0
Intangible assets income tax liability	$252,707	$176,414

FAIR_VALUE_MEASUREMENTS_At_Rep

FAIR VALUE MEASUREMENTS At Reporting Date Using (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
FAIR VALUE MEASUREMENTS At Reporting Date Using
Bankers acceptance notes	$458,233	$336,003
Total	458,233	336,003
Bankers acceptance notes Level 1	0	0
Total Level 1	0	0
Bankers acceptance notes Level 2	458,233	336,003
Total Level 2	458,233	336,003
Bankers acceptance notes Level 3	0	0
Total Level 3	$0	$0

Preferred_Common_Stock_And_War

Preferred Common Stock And Warrants (Details) (USD $)	Dec. 31, 2014
Preferred Common Stock And Warrants
Common shares authorized	95,000,000
Preferred shares authorized	5,000,000
Number of common stock shares to purchase by warrants outstaning and exercisable	150,000
Warrants start range exercise price	$3
Warrants end range exercise price	$3.80

2010_Stock_Option_Plan_Details

2010 Stock Option Plan (Details) (USD $)	Dec. 31, 2014	Nov. 12, 2010
STOCKHOLDERS EQUITY 2010 Stock Option Plan
Number of common shares		4,000,000
Number of common shares purchased by options	25,000
Stock options granted	100,000
Exercise price per share expired unexercised.	$2.54
shares of restricted stock granted and outstanding under the 2010 Incentive Plan	175,000

Contractual_Commitments_Detail

Contractual Commitments (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Contractual Commitments Details
Company made payments as per Construction agreement	$4,637,671	$25,474,525

CONCENTRATIONS_Details

CONCENTRATIONS (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
CONCENTRATIONS Details
Customer accounted for sales	16.20%	10.00%
Supplier accounted for raw material purchases	26.50%	18.70%
Customer accounted accounts receivable 1st time	17.70%	14.50%
Customer accounted accounts receivable 2nd time	0.00%	11.20%
First product accounted for revenue	49.00%	35.00%
Second product accounted for revenue	12.00%	13.00%
Third Product accounted for revenue	11.00%	10.00%